Immune-Related Skin Toxicities to Checkpoint Inhibitors Therapy

    May 2022 in “ Голова и шея. ”
    Marina Sekacheva, Ekaterina V. Orlova, Gaiane A. Gabrielian, Л. М. Смирнова, A. A. Tulsky
    TLDR Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
    The document discussed the increasing use of biologic therapies targeting immune checkpoints, such as CTLA-4 and PD-1/PD-L1, which led to a range of immune-related adverse events (irAEs), particularly affecting the skin. The severity of these cutaneous irAEs ranged from mild dermatitis to severe toxic epidermal necrolysis, with the most common being nonspecific maculopapular rash and pruritus. The document also reported a case of a patient with metastatic renal cell carcinoma (mRCC) undergoing immune checkpoint inhibitors therapy who developed a psoriasiform skin lesion.
    Discuss this study in the Community →